Many Patients with Metastatic NSCLC Remain Untreated Despite Therapeutic Advances
A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.
A retrospective cohort study of Medicare beneficiaries diagnosed with metastatic non‑small cell lung cancer (mNSCLC) found that nearly half of older adults do not receive systemic anticancer therapy despite advances in immunotherapy and targeted agents that improve survival and quality of life.
The finding highlights persistent gaps in referral patterns, access to care, and perceptions surrounding lung cancer treatment outcomes, underscoring the need for earlier detection, timely referral to oncology specialists, and education of patients and providers about modern, tolerable therapies.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT